<DOC>
	<DOCNO>NCT00870844</DOCNO>
	<brief_summary>The primary purpose study determine whether carbamylated erythropoietin ( CEPO ) dose daily 5 day safe treatment patient suffer acute ischemic stroke .</brief_summary>
	<brief_title>Safety Pharmacokinetic Study Carbamylated Erythropoietin ( CEPO ) Treat Patients With Acute Ischemic Stroke</brief_title>
	<detailed_description>Acute ischemic stroke major cause death severe disability . The naturally occur hormone , erythropoietin ( EPO ) , able protect various neuronal tissue ischemic injury beneficial animal model acute ischemic stroke . Lu AA24493 modify ( carbamylated ) version EPO , neuroprotective without haematopoietic side effect . Lu AA24493 develop treatment patient acute ischemic stroke .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Ischemia</mesh_term>
	<mesh_term>Cerebral Infarction</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Age 50 90 year Clinical diagnosis acute ischemic stroke Measurable strokerelated deficit Patient stable Treatment initiate 0 hour 48 hour onset stroke Expected hospital stay least 120 hour first dose study medication If female childbearing potential Primary intracerebral haemorrhage ( ICH ) , parenchymal haemorrhagic transformation infarction ( type PHI PHII define ECASS ) , subarachnoid haemorrhage ( SAH ) , arteriovenous malformation ( AVM ) , cerebral aneurysm , cerebral neoplasm Treated thrombolytic &lt; 24 hour ( &gt; 24 hour exclude ICH eligible ) Score &gt; =1 NIHSS item 1a Prestroke mRS score &gt; =2 Uncontrolled hypertension Previous treatment erythropoietin Previous exposure Lu AA24493</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>Acute ischemic stroke</keyword>
	<keyword>Erythropoietin</keyword>
	<keyword>Carbamylated</keyword>
	<keyword>Neuroprotection</keyword>
</DOC>